Citigroup Inc. Takes Position in Lantheus Holdings, Inc. (LNTH)
Citigroup Inc. purchased a new stake in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) in the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 35,014 shares of the medical equipment provider’s stock, valued at approximately $618,000. Citigroup Inc. owned 0.09% of Lantheus Holdings as of its most recent filing with the Securities & Exchange Commission.
A number of other institutional investors and hedge funds also recently bought and sold shares of LNTH. Bank of New York Mellon Corp grew its position in Lantheus Holdings by 6.3% during the first quarter. Bank of New York Mellon Corp now owns 68,473 shares of the medical equipment provider’s stock valued at $856,000 after buying an additional 4,084 shares during the period. Parametric Portfolio Associates LLC grew its position in Lantheus Holdings by 28.9% during the first quarter. Parametric Portfolio Associates LLC now owns 22,530 shares of the medical equipment provider’s stock valued at $282,000 after buying an additional 5,058 shares during the period. Systematic Financial Management LP bought a new position in Lantheus Holdings during the first quarter valued at about $1,314,000. California Public Employees Retirement System grew its position in Lantheus Holdings by 29.2% during the first quarter. California Public Employees Retirement System now owns 77,800 shares of the medical equipment provider’s stock valued at $973,000 after buying an additional 17,600 shares during the period. Finally, MARSHALL WACE ASIA Ltd bought a new position in Lantheus Holdings during the first quarter valued at about $1,043,000. Institutional investors own 84.34% of the company’s stock.
Lantheus Holdings, Inc. (LNTH) opened at 18.70 on Thursday. Lantheus Holdings, Inc. has a 12 month low of $7.61 and a 12 month high of $19.00. The company has a market cap of $698.45 million, a price-to-earnings ratio of 25.55 and a beta of 0.91. The firm’s 50-day moving average is $17.60 and its 200-day moving average is $17.60.
Lantheus Holdings (NASDAQ:LNTH) last released its quarterly earnings results on Tuesday, August 1st. The medical equipment provider reported $0.42 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.24 by $0.18. The business had revenue of $88.83 million during the quarter, compared to the consensus estimate of $80.56 million. Lantheus Holdings had a negative return on equity of 37.47% and a net margin of 8.44%. The business’s quarterly revenue was up 13.9% compared to the same quarter last year. During the same period in the previous year, the company posted $0.24 EPS. On average, analysts anticipate that Lantheus Holdings, Inc. will post $1.12 EPS for the current fiscal year.
COPYRIGHT VIOLATION WARNING: “Citigroup Inc. Takes Position in Lantheus Holdings, Inc. (LNTH)” was first published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this piece of content on another website, it was stolen and reposted in violation of U.S. & international trademark & copyright legislation. The legal version of this piece of content can be read at https://www.thecerbatgem.com/2017/10/12/citigroup-inc-takes-position-in-lantheus-holdings-inc-lnth.html.
In related news, Director Derace L. Schaffer sold 15,000 shares of the business’s stock in a transaction that occurred on Wednesday, September 13th. The stock was sold at an average price of $17.50, for a total transaction of $262,500.00. Following the completion of the transaction, the director now directly owns 48,730 shares in the company, valued at approximately $852,775. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, insider Michael P. Duffy sold 20,000 shares of the business’s stock in a transaction that occurred on Monday, September 11th. The shares were sold at an average price of $16.45, for a total value of $329,000.00. Following the transaction, the insider now owns 184,218 shares of the company’s stock, valued at $3,030,386.10. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 896,344 shares of company stock valued at $15,319,126. Corporate insiders own 2.30% of the company’s stock.
Several equities analysts recently weighed in on the stock. Jefferies Group LLC restated a “buy” rating and set a $22.00 price target on shares of Lantheus Holdings in a research report on Thursday. Cantor Fitzgerald assumed coverage on shares of Lantheus Holdings in a research report on Monday, July 17th. They set an “overweight” rating and a $22.00 price target for the company. Zacks Investment Research lowered shares of Lantheus Holdings from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, July 5th. BidaskClub lowered shares of Lantheus Holdings from a “strong-buy” rating to a “buy” rating in a research report on Thursday, August 17th. Finally, Credit Suisse Group increased their target price on shares of Lantheus Holdings from $14.00 to $19.00 and gave the stock a “neutral” rating in a research report on Wednesday, August 2nd. Two investment analysts have rated the stock with a hold rating and four have given a buy rating to the company. Lantheus Holdings has an average rating of “Buy” and a consensus price target of $18.60.
Lantheus Holdings Company Profile
Lantheus Holdings, Inc is engaged in the development, manufacture and commercialization of diagnostic medical imaging agents and products that assist clinicians in the diagnosis and treatment of cardiovascular and other diseases. Its imaging agents and products are used across a range of imaging modalities, including echocardiography and nuclear imaging.
Want to see what other hedge funds are holding LNTH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Lantheus Holdings, Inc. (NASDAQ:LNTH).
Receive News & Stock Ratings for Lantheus Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lantheus Holdings Inc. and related stocks with our FREE daily email newsletter.